WDC
40
2
MA
60
-2
TGNA
72
5
NWS
62
-2
VTR
58
-2
FTI
69
-2
NI
70
-2
KMX
53
-2
DVN
32
3
CMG
43
-4
AA
51
-3
MUR
38
-4
PG
63
-5
GILD
68
-4
NVDA
51
-3
SWKS
46
3
ORCL
54
-2
AN
38
-2
ES
45
4
NAVI
25
-2
WDC
40
2
MA
60
-2
TGNA
72
5
NWS
62
-2
VTR
58
-2
FTI
69
-2
NI
70
-2
KMX
53
-2
DVN
32
3
CMG
43
-4
AA
51
-3
MUR
38
-4
PG
63
-5
GILD
68
-4
NVDA
51
-3
SWKS
46
3
ORCL
54
-2
AN
38
-2
ES
45
4
NAVI
25
-2
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
48

ASND
Ascendis Pharma AS

Last Price:
$161.75
Seasonality Move:
-9.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $393.6M
Cash Flow: $-90.9M
Price / Cash Flow: 0
Annual Sales: $-1.84
Price / Book: 0

Profitability

EPS (TTM): -7.12870
Net Income (TTM): $-410.2M
Gross Margin: $345.7M
Return on Equity: -880.05%
Return on Assets: -40.69%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 6 years for ASND is 87.83%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 78.25% of Gross Profit Margin.
  • The Research & Development expenses have been 84.43% of Revenue.
  • The Net Earning history of ASND is -103.97% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -8.1
Current Ratio: 1.17
Quick Ratio: 0.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 94.57

ASND Technical Analysis vs Fundamental Analysis

Sell
48
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?